Innovation AveNEW: unlocking microbial dark matter, making biophysical data accessible and targeting the undruggable

Written by Annie Coulson (Digital Editor)
Analytical chemistry Drug discovery and development Interviews Lab design and machinery Molecular biology

The Society for Laboratory Automation and Screening (SLAS)’s international and European conferences feature Innovation AveNEW, an area of the exhibition dedicated to startups and emerging companies. At SLAS Europe 2025 (20–22 May; Hamburg, Germany), we took a stroll down Innovation AveNEW and spoke to three companies that caught our eye: MyxoTech, Instromeda and ThirdLaw Molecular. MyxoTech: unlocking microbial dark matter MyxoTech (Saarbrücken, Germany) is a start-up that offers a library of small molecules derived from myxobacteria for use in the pharmaceutical industry. At SLAS, we spoke with the CEO and one of the founders of MyxoTech, Peter Sullivan. What is...

To view this content, please register now for access

Join our member community for FREE to access a collection of journal and online-only features, including:

  • Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
  • The latest news and journal updates delivered straight to your inbox when you want it
  • Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
  • Priority registration to webinars, panel discussions and events
  • Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!